Zenas BioPharma, Inc.
ZBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $406 | $330 | $342 |
| - Cash | $116 | $44 | $197 | $320 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | – | $363 | $135 | $24 |
| Revenue | $0 | $0 | $10 | $5 |
| % Growth | – | -100% | 100% | – |
| Gross Profit | -$5 | -$43 | $10 | $5 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$51 | -$55 | -$34 | -$56 |
| % Margin | – | – | -337.6% | -1,111.8% |
| Net Income | -$51 | -$52 | -$34 | -$53 |
| % Margin | – | – | -335.7% | -1,052.1% |
| EPS Diluted | -1.22 | -1.25 | -0.8 | -1.26 |
| % Growth | 2.4% | -56.2% | 36.5% | – |
| Operating Cash Flow | -$41 | -$42 | -$37 | -$39 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$41 | -$42 | -$37 | -$39 |